EM-T3Pharmacoepidemiology and Drug Safety2020-10-17第 30 卷第 1 期，65-77
Direct healthcare costs of chronic kidney disease management in Italy: What cost‐savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis‐stimulating agents?
